Breakthrough in Urethral Stricture Treatment Reaches Japan
On March 31, 2025, GN Corporation successfully transferred its BEES-HAUS cell therapy in japan, technology from India to Japan, marking a milestone in regenerative medicine. This innovative treatment for male urethral stricture has now entered clinical application at Edogawa Hospital, Tokyo, under the leadership of Dr. Akio Horiguchi, as reported in the International Meeting of Reconstructive Urology (IMORU), Hamburg, Germany.
BEES-HAUS: A Revolutionary Approach to Urethral Stricture
BEES-HAUS (Buccal Epithelium Engraftment System – Hybrid Application for Urethral Stricture) was originally conceptualized by Dr. Suryaprakash, a Hyderabad-based urologist. His research, which began in 2012, focused on using buccal mucosal cells for treating urethral strictures. This innovation was first presented at NCRM NICHE 2017 in Tokyo, leading to a collaboration with Dr. Horiguchi from Japan’s National Defence Medical College (NDMC).
Between 2018 and 2023, extensive pre-clinical trials confirmed the successful engraftment of cultured cells, paving the way for clinical application. In 2025, Edogawa Hospital initiated the first-ever BEES-HAUS clinical transplant, signifying a major step forward in tissue engineering and regenerative urology.
Key Highlights of BEES-HAUS Therapy
- Minimally Invasive Approach: Uses a small buccal tissue sample, reducing oral morbidity.
- Cell-Based Regeneration: Cultured cells replace damaged urethral epithelium, ensuring long-term healing.
- Hybrid Therapy: Integrates 2D fibroblast-like cells (IGF-1 secretion for paracrine healing) and 3D polymer-based cultured cells, making it the first of its kind in regenerative medicine.
- Prevention of Recurrence: Unlike traditional urethroplasty, BEES-HAUS therapy significantly reduces the risk of disease recurrence.
- Efficient Tissue Transport: Standardized cell and tissue transportation using a nano-polymer cocktail, ensuring high success rates.
Global Expansion: India, Japan, and Beyond
Following its successful technology transfer to Japan, GN Corporation has signed a Memorandum of Understanding (MoU) with Soulsynergy, Mauritius. This partnership aims to expand cell-based therapies for urethral strictures, corneal regeneration, and AIET (Autologous Immune Enhancement Therapy) for cancer, positioning Mauritius as a key medical tourism hub for Africa and Indian Ocean Rim countries.
The collaboration between India and Japan in cell therapy and regenerative medicine demonstrates the potential of interdisciplinary research to revolutionize global healthcare. With BEES-HAUS technology now in clinical use, this breakthrough sets the stage for future advancements in regenerative urology worldwide.
